PMS-002

PMS-002 is a preclinical small molecule program developed by Qingdao Primedicine Pharmaceutical, focusing on the allosteric modulation of N-methyl-D-aspartate (NMDA) receptor subtypes. The program encompasses several specific candidates tailored for different neurological and psychiatric indications: **Npam 43** is being developed for the treatment of cerebral stroke, **Npam 105** is targeted at Alzheimer's disease, and **Npam 217** is intended for schizophrenia. By acting as subtype-selective allosteric modulators, these compounds aim to fine-tune glutamatergic neurotransmission, which is frequently dysregulated in these conditions, potentially offering a more targeted therapeutic approach compared to orthosteric NMDA receptor ligands.